Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mück

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
British Journal of Clinical Pharmacology|February 26, 2000
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: linking in vitro with in vivo informationW Mück
Die Pharmazie|October 16, 1999
Quantitative analysis of pharmacokinetic study samples by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS)W Mück
Drugs|September 18, 1998
Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactionsW Mück
Clinical Pharmacokinetics|September 8, 2000
Clinical pharmacokinetics of cerivastatinW Mück
Drug Safety|October 26, 2001
Clinical-pharmacological strategies to assess drug interaction potential during drug developmentJ Kuhlmann, W Mück
Die Pharmazie|February 1, 1994
Bioanalytics of nimodipine--an overview of methodsW Mück, H Bode
Drugs & Aging|March 1, 1995
Nimodipine. Potential for drug-drug interactions in the elderlyW Mück, G Ahr, J Kuhlmann
International Journal of Clinical Pharmacology and Therapeutics|July 1, 1996
The influence of age on the pharmacokinetics of nimodipineW Mück, H P Breuel, J Kuhlmann
Journal of Pharmaceutical and Biomedical Analysis|January 1, 1989
Analytical oxidation of reserpineS Ebel, W Mück, F J Placke
International Journal of Clinical Pharmacology and Therapeutics|July 13, 2000
Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or eveningW Mück, R Frey, S Unger, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
British Journal of Clinical Pharmacology|February 26, 2000
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: linking in vitro with in vivo informationW Mück
Die Pharmazie|October 16, 1999
Quantitative analysis of pharmacokinetic study samples by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS)W Mück
Drugs|September 18, 1998
Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactionsW Mück
Clinical Pharmacokinetics|September 8, 2000
Clinical pharmacokinetics of cerivastatinW Mück
Drug Safety|October 26, 2001
Clinical-pharmacological strategies to assess drug interaction potential during drug developmentJ Kuhlmann, W Mück
Die Pharmazie|February 1, 1994
Bioanalytics of nimodipine--an overview of methodsW Mück, H Bode
Drugs & Aging|March 1, 1995
Nimodipine. Potential for drug-drug interactions in the elderlyW Mück, G Ahr, J Kuhlmann
International Journal of Clinical Pharmacology and Therapeutics|July 1, 1996
The influence of age on the pharmacokinetics of nimodipineW Mück, H P Breuel, J Kuhlmann
Journal of Pharmaceutical and Biomedical Analysis|January 1, 1989
Analytical oxidation of reserpineS Ebel, W Mück, F J Placke
International Journal of Clinical Pharmacology and Therapeutics|July 13, 2000
Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or eveningW Mück, R Frey, S Unger, et al.
Pageof 4